Key result
Cardioselective beta-blockers benefit COPD patients only when guideline-directed cardiac indications are present.
Why the study?
Controversies regarding beta-blocker use in COPD have been longstanding, with underutilization in eligible patients despite safety evidence, and inconsistent findings across observational studies and recent randomized trial data.
What is the role of beta-blockers in the management of patients with chronic obstructive pulmonary disease (COPD) with and without cardiovascular disease?
What is the role of beta-blockers in the management of patients with chronic obstructive pulmonary disease (COPD) with and without cardiovascular disease?
This narrative review synthesizes evidence including the BLOCK COPD trial to recommend that beta-blockers be avoided in COPD patients lacking a clear cardiovascular indication, while emphasizing that cardioselective beta-blockers remain indicated and underutilized in COPD patients with ischemic heart disease, heart failure, or arrhythmias.
Answers are grounded in this paper and cite their sources.
Supports restricting beta-blockers to COPD patients with cardiac indications; leaves open prospective validation of cardioselective agents.
INTRODUCTION: Controversies regarding the use of beta-blocker in chronic obstructive pulmonary disease (COPD) have been longstanding and based on inconsistent data. COPD and cardiovascular disease have many shared risk factors and potentially overlapping pathophysiologic mechanisms. Beta-blockers, a mainstay of treatment in ischemic heart disease, congestive heart failure, and cardiac arrhythmia, remain underutilized in COPD patients despite considerable evidence of safety. Furthermore, observational studies indicated the potential benefits of beta-blockers in COPD via a variety of possible mechanisms. Recently, a randomized controlled trial of metoprolol versus placebo failed to show a reduction in COPD exacerbation risk in subjects with moderate to severe COPD and no absolute indication for beta-blocker use. AREAS COVERED: Physiology of beta-adrenergic receptors, links between COPD and cardiovascular disease, and the role of beta-blockers in COPD management are discussed. EXPERT COMMENTARY: Beta-blockers should not be used to treat COPD patients who do not have conditions with clear guideline-directed recommendations for their use. Vigilance is recommended in prescribing these medications for indications where another drug class could be utilized.
No takes yet. Share an insight, caveat, or question.
Wade et al. (2020) conducted a review in Chronic obstructive pulmonary disease (COPD) and concomitant cardiovascular disease. Beta-blockers was evaluated. Beta-blockers should not be used to treat COPD patients without guideline-directed cardiac indications, whereas cardioselective agents are recommended for COPD patients with ischemic heart disease, heart failure, or arrhythmias.
Synapse has enriched 10 related papers. Consider them for comparative context: